Healthcare Industry News: Ivera Medical
News Release - August 26, 2008
BD (Becton, Dickinson and Company) Licenses Intellectual Property to Ivera Medical CorporationSAN DIEGO--(HSMN NewsFeed)--Ivera Medical Corporation, a San Diego (CA) based medical device company, today announced an exclusive license agreement with BD (Becton, Dickinson and Company), a global medical technology company, for the worldwide rights to selected BD-issued and pending patents for an intravenous (I.V.) port protector designed to reduce the potential for healthcare-acquired bloodstream infections.
“This license agreement between our two companies confirms our mutual commitment to assist healthcare providers in their efforts to reduce bloodstream infections. We believe a significant number of these infections are caused by touch or airborne contamination of needleless I.V. ports,” Bob Rogers, Chief Executive Officer of Ivera Medical said, in making the announcement.
Healthcare-acquired bloodstream infections dramatically increase a patient’s hospital length of stay, potential mortality and the overall cost of care, according to a recently released study by the Pennsylvania Health Care Cost Containment Council.
Every year in the United States alone healthcare-acquired bloodstream infections are estimated to cost the healthcare system over $5 billion.
“The licensing agreement between BD and Ivera broadens our existing patent applications and removes potential patent issues so we can move forward with the worldwide marketing and sales of the Curos Port Protector,” Jack Saladow, Ivera Vice President of Marketing and Sales said.
“We are very pleased with this exclusive license from BD, and we are looking forward to the expansion of Ivera Medical’s product offering,” Rogers added.
About Ivera Medical Corporation:
Ivera Medical develops, manufactures and markets innovative, high quality medical devices to improve healthcare providers’ management and control of patient infections.
Source: Ivera Medical
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.